NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 22, 2006--Senesco Technologies, Inc. (“Senesco” or the “Company”) (AMEX: SNT) announced today that a preclinical animal study has shown that the Company’s proprietary gene technology increases the survivability of islets isolated for transplantation. Islets are the insulin producing cells located in the mammalian pancreas.
